{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:39:45Z","timestamp":1794947985313,"version":"4.9.1"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNC0000001"],"award-info":[{"award-number":["PNC0000001"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.metabol.2024.156080","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T08:18:34Z","timestamp":1732004314000},"page":"156080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance"],"prefix":"10.1016","volume":"162","author":[{"given":"Angelo","family":"Armandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Caviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0025","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0030","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/metabo11030155","article-title":"Insulin resistance across the spectrum of nonalcoholic fatty liver disease","volume":"11","author":"Armandi","year":"2021","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","article-title":"Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease","volume":"71","author":"Rosso","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156080_bb0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/164_2021_561","article-title":"NAFLD and NASH: the metabolically diseased liver","volume":"274","author":"Armandi","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.metabol.2024.156080_bb0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.14910","article-title":"Natural history of NASH","volume":"41 Suppl 1(Suppl 1)","author":"Armandi","year":"2021","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0065","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0075","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156080_bb0080","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0090","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0100","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2021.09.024","article-title":"Asian perspective on NAFLD-associated HCC","volume":"76","author":"Yip","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0105","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/hep.21103","article-title":"Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C","volume":"43","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0110","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.metabol.2024.156080_bb0115","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities","volume":"4","author":"Golabi","year":"2020","journal-title":"Hepatol Commun."},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0120","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.metabol.2024.156080_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0130","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.metabol.2024.156080_bb0140","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/00365521.2022.2062257","article-title":"Hepatocellular carcinoma in Stockholm, Sweden 2003\u20132018: a population-based cohort study","volume":"57","author":"Nor\u00e9n","year":"2022","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.metabol.2024.156080_bb0150","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0160","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/hep4.1915","article-title":"Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: data from the United States Scientific Registry of Transplant Recipients","volume":"6","author":"Stepanova","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2023","journal-title":"Hepatol Commun."},{"issue":"11","key":"10.1016\/j.metabol.2024.156080_bb0170","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0180","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-014-0548-5","article-title":"Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies","volume":"8","author":"Oda","year":"2015","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/LVT.0000000000000007","article-title":"Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium","volume":"29","author":"Verna","year":"2023","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000535943","volume":"13","author":"Kim","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.metabol.2024.156080_bb0195","article-title":"Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes","author":"Chen","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0200","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep."},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.metabol.2024.156080_bb0210","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s12072-023-10616-8","article-title":"Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study","volume":"18","author":"Huang","year":"2024","journal-title":"Hepatol Int."},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0215","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12876-021-01978-0","article-title":"Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study","volume":"21","author":"Pinyopornpanish","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0220","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12072-023-10498-w","article-title":"Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study","volume":"17","author":"Prabhakar","year":"2023","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0225","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jgh.14867","article-title":"The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis","volume":"35","author":"Tobari","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0230","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/liv.14087","article-title":"Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis","volume":"39","author":"Bengtsson","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.156080_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156080_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","author":"Chen","year":"2024","journal-title":"Hepatology"},{"issue":"10290","key":"10.1016\/j.metabol.2024.156080_bb0245","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156080_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.metabol.2024.156080_bb0255","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0260","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","article-title":"Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?","volume":"158","author":"Gehrke","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.metabol.2024.156080_bb0265","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0270","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","article-title":"In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases","volume":"37","author":"Seki","year":"2002","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0280","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/path.5871","article-title":"Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis","volume":"257","author":"Di Maira","year":"2022","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0285","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"issue":"7593","key":"10.1016\/j.metabol.2024.156080_bb0290","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0295","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0300","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"issue":"7374","key":"10.1016\/j.metabol.2024.156080_bb0305","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156080_bb0310","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology. 2024 Feb 13:https:\/\/doi.org\/10.1097\/HEP.0000000000000786.","DOI":"10.1097\/HEP.0000000000000786"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0315","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0320","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0325","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0330","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0335","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jhep.2011.02.035","article-title":"DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH","volume":"55","author":"G\u00e4bele","year":"2011","journal-title":"J Hepatol"},{"issue":"24","key":"10.1016\/j.metabol.2024.156080_bb0340","article-title":"A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR\u03b1 and PCK1","volume":"S1550-4131","author":"Gallage","year":"2024","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PloS One"},{"issue":"7499","key":"10.1016\/j.metabol.2024.156080_bb0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"FXR is a molecular target for the effects of vertical sleeve gastrectomy","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.metabol.2024.156080_bb0355","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0360","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/gutjnl-2015-310283","article-title":"Microbiota-induced obesity requires farnesoid X receptor","volume":"66","author":"Pars\u00e9us","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0365","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"issue":"10215","key":"10.1016\/j.metabol.2024.156080_bb0370","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156080_bb0375","unstructured":"EASL Policy Statement: risk-based surveillance for hepatocellular carcinoma among patients with cirrhosis. Available at: https:\/\/easl.eu\/publication\/easl-policy-statement-risk-based\/."},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0380","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","article-title":"Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis","volume":"75","author":"Gupta","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.08.012","article-title":"Diagnostic performance of abbreviated MRI for HCC detection in patients with non-alcoholic fatty liver disease","volume":"14","author":"Soundararajan","year":"2024","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0390","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0395","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0400","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0405","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2022.08.036","article-title":"Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era?","volume":"78","author":"Parikh","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156080_bb0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2407-8-200","article-title":"AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease","volume":"8","author":"Beale","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.metabol.2024.156080_bb0415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.hbpd.2022.05.003","volume":"21","author":"Guan","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.metabol.2024.156080_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155800","article-title":"Midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma","volume":"11","author":"Vongsuvanh","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156080_bb0425","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.30753","article-title":"Plasma osteopontin level in chronic liver disease and hepatocellular carcinoma","volume":"15","author":"Fouad","year":"2015","journal-title":"Hepat Mon"},{"key":"10.1016\/j.metabol.2024.156080_bb0430","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.3390\/curroncol29080431","article-title":"Liver cancer-specific isoform of serine protease inhibitor kazal for the detection of hepatocellular carcinoma: results from a pilot study in patients with dysmetabolic liver disease","volume":"29","author":"Caviglia","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0435","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12876-023-02786-4","article-title":"Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis","volume":"23","author":"Kawanaka","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2024.156080_bb0440","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cca.2007.05.014","article-title":"Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients","volume":"383","author":"Giannelli","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"48","key":"10.1016\/j.metabol.2024.156080_bb0445","doi-asserted-by":"crossref","first-page":"8343","DOI":"10.3748\/wjg.v27.i48.8343","article-title":"Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients","volume":"27","author":"Gil-G\u00f3mez","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0450","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00535-017-1398-y","article-title":"Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma","volume":"53","author":"Koyama","year":"2018","journal-title":"J Gastroenterol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156080_bb0455","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/hepr.13826","article-title":"Serum levels of immunoglobulin M-free inhibitors of macrophage\/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"52","author":"Okanoue","year":"2022","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0460","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/nu15010066","article-title":"The FIB-4 index predicts the development of liver-related events, extrahepatic cancers, and coronary vascular disease in patients with NAFLD","volume":"15","author":"Kamada","year":"2022","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.metabol.2024.156080_bb0465","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3390\/jcm11092466","article-title":"Non-invasive tests of liver fibrosis help in predicting the development of hepatocellular carcinoma among patients with NAFLD","volume":"11","author":"Pons","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0470","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/00325481.2022.2058285","article-title":"Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population","volume":"134","author":"Rigor","year":"2022","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0475","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1841","article-title":"Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD","volume":"6","author":"Vieira Barbosa","year":"2022","journal-title":"Hepatol Commun."},{"issue":"15","key":"10.1016\/j.metabol.2024.156080_bb0480","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3390\/jcm10153392","article-title":"The APAC score: a novel and highly performant serological tool for early diagnosis of hepatocellular carcinoma in patients with liver cirrhosis","volume":"10","author":"Lambrecht","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.metabol.2024.156080_bb0485","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/hepr.13938","article-title":"Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease","volume":"53","author":"Miura","year":"2023","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280647","article-title":"Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study","volume":"18","author":"Davitkov","year":"2023","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0495","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000183","article-title":"Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis","volume":"7","author":"Behari","year":"2023","journal-title":"Hepatol Commun."},{"key":"10.1016\/j.metabol.2024.156080_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1198871","article-title":"Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis","volume":"13","author":"Albhaisi","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0505","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/liv.14301","article-title":"Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease","volume":"40","author":"Shili-Masmoudi","year":"2020","journal-title":"Liver Int"},{"issue":"18","key":"10.1016\/j.metabol.2024.156080_bb0510","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.3390\/cancers13184567","article-title":"Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.metabol.2024.156080_bb0515","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","volume":"S0168-8278","author":"Sharma","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0520","article-title":"External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population","volume":"3","author":"\u00c5str\u00f6m","year":"2021","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0525","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0530","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1053\/j.gastro.2023.06.027","article-title":"Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) study","volume":"165","author":"Reddy","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0535","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1055-9965.EPI-21-0754","article-title":"Serum biomarkers of iron status and risk of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease","volume":"31","author":"Yu","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.metabol.2024.156080_bb0540","unstructured":"Armandi A, Sanavia T, Younes R, Caviglia GP, Rosso C, Govaere O, et al. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2024 Apr 5;73(5):825-834. doi: 10.1136\/gutjnl-2023-330815.Muhammad Yusuf AN, Raja Ali RA, Muhammad Nawawi KN, Mokhtar NM. Potential biomarkers in NASH-induced liver cirrhosis with hepatocellular carcinoma: A preliminary work on roles of exosomal miR-182, miR-301a, and miR-373. Malays J Pathol. 2020;42(3):377-384."},{"issue":"22","key":"10.1016\/j.metabol.2024.156080_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216043","article-title":"Circulating extracellular vesicle-derived microRNAs as novel diagnostic and prognostic biomarkers for non-viral-related hepatocellular carcinoma","volume":"24","author":"Boonkaew","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.metabol.2024.156080_bb0550","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000510366","article-title":"TERT promoter mutation in serum cell-free DNA is a diagnostic marker of primary hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"99","author":"Akuta","year":"2021","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0555","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1354750X.2021.2008009","article-title":"Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a meta-analysis","volume":"27","author":"Zhang","year":"2022","journal-title":"Biomarkers"},{"issue":"12","key":"10.1016\/j.metabol.2024.156080_bb0560","article-title":"Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: a systematic review and meta-analysis","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156080_bb0565","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/liv.13867","article-title":"Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: a meta-analysis","volume":"38","author":"Liu","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0570","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12876-023-02685-8","article-title":"Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"2019","key":"10.1016\/j.metabol.2024.156080_bb0575","article-title":"The diagnostic value of microRNAs as a biomarker for hepatocellular carcinoma: a meta-analysis","author":"Jiang","year":"2019","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0580","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/00365521.2018.1459824","article-title":"Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis","volume":"53","author":"Caviglia","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156080_bb0585","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/cancers13102305","article-title":"Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"13","author":"Caviglia","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.metabol.2024.156080_bb0590","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.3390\/cancers12113218","article-title":"Alpha-fetoprotein, protein induced by vitamin K absence or antagonist II and glypican-3 for the detection and prediction of hepatocellular carcinoma in patients with cirrhosis of viral etiology","volume":"12","author":"Caviglia","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"8","key":"10.1016\/j.metabol.2024.156080_bb0595","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/liv.14475","article-title":"The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy","volume":"40","author":"Loglio","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0600","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/apt.16685","article-title":"Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents","volume":"55","author":"Degasperi","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156080_bb0605","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jfma.2021.08.003","article-title":"Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis","volume":"121","author":"Su","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0610","first-page":"94","article-title":"Identification of the best cut-off value of PIVKA-II for the surveillance of patients at risk of hepatocellular carcinoma development","volume":"12","author":"Caviglia","year":"2023","journal-title":"Biology (Basel)"},{"issue":"S1","key":"10.1016\/j.metabol.2024.156080_bb0615","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.dld.2024.01.019","article-title":"Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up","volume":"56","author":"Caviglia","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0620","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.metabol.2024.156080_bb0625","article-title":"Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score","volume":"S1499-3872","author":"Sun","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0630","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3390\/cancers15061659","article-title":"Prognostic value of simple non-invasive tests for the risk stratification of incident hepatocellular carcinoma in cirrhotic individuals with non-alcoholic fatty liver disease","volume":"15","author":"Armandi","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.metabol.2024.156080_bb0635","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0640","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.metabol.2024.156080_bb0645","article-title":"Validation of noninvasive markers for HCC risk stratification in 1389 patients with biopsy-proven NAFLD","volume":"S2772-5723","author":"Toyoda","year":"2023","journal-title":"Gastro Hep Advances"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0650","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease","volume":"19","author":"Petta","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.metabol.2024.156080_bb0655","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2024.156080_bb0660","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.28746","article-title":"Nonalcoholic fatty liver disease and metabolic syndrome: shared genetic basis of pathogenesis","volume":"64","author":"Sookoian","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156080_bb0665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.metabol.2024.156080_bb0670","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2024.156080_bb0675","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.05.035","article-title":"Genetic profiling of hepatocellular carcinoma using next-generation sequencing","volume":"65","author":"Schulze","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0680","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156080_bb0685","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2024.156080_bb0690","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/hep.26767","article-title":"Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: eidence from a meta-analysis of individual participant data","volume":"59","author":"Trepo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156080_bb0695","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jhep.2021.02.030","article-title":"Reply to: Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease","volume":"74","author":"Jamialahmadi","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156080_bb0700","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.cgh.2023.04.024","article-title":"Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease","volume":"21","author":"Rosso","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156080_bb0705","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1186\/s12885-019-6173-4","article-title":"Association of TM6SF2 rs58542926 T\/C gene polymorphism with hepatocellular carcinoma: a meta-analysis","volume":"19","author":"Tang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.metabol.2024.156080_bb0710","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.4251\/wjgo.v15.i12.2225","article-title":"Association of MBOAT7 rs641738 polymorphism with hepatocellular carcinoma susceptibility: a systematic review and meta-analysis","volume":"15","author":"Lai","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.metabol.2024.156080_bb0715","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156080_bb0720","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/apt.17638","article-title":"The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma","volume":"58","author":"Innes","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156080_bb0725","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156080_bb0730","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-021-03243-6","article-title":"Improving reporting standards for polygenic scores in risk prediction studies","volume":"591","author":"Wand","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156080_bb0735","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156080_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282309","article-title":"Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score","volume":"18","author":"Thrift","year":"2023","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156080_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156080_bb0750","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejim.2024.01.005","article-title":"Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease","volume":"122","author":"Armandi","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"14","key":"10.1016\/j.metabol.2024.156080_bb0755","article-title":"Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"10213","key":"10.1016\/j.metabol.2024.156080_bb0760","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.metabol.2024.156080_bb0765","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.metabol.2024.156080_bb0770","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156080_bb0775","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging Pharmacotherapies for Obesity: A Systematic Review","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0780","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156080_bb0785","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0790","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0795","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156080_bb0800","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.16752","article-title":"Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis","author":"Passos","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156080_bb0805","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","article-title":"Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes","volume":"73","author":"Wester","year":"2024","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0810","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156080_bb0815","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156080_bb0820","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156080_bb0825","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156080_bb0830","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156080_bb0835","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156080_bb0840","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156080_bb0845","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156080_bb0850","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156080_bb0855","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7326\/M18-2753","article-title":"Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide swedish population","volume":"171","author":"Simon","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.metabol.2024.156080_bb0860","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.metabol.2024.156080_bb0865","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0870","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"7203","key":"10.1016\/j.metabol.2024.156080_bb0875","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.metabol.2024.156080_bb0880","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.metabol.2024.156080_bb0885","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/gut.2008.159293","article-title":"Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition","volume":"57","author":"Fujisawa","year":"2008","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.metabol.2024.156080_bb0890","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156080_bb0895","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"173","author":"Thomas","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.metabol.2024.156080_bb0900","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.metabol.2024.156080_bb0905","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.22.01740","article-title":"Increased risk of young-onset digestive tract cancers among young adults age 20\u201339 years with nonalcoholic fatty liver disease: a nationwide cohort study","volume":"41","author":"Park","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156080_bb0910","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"44","author":"Souza","year":"2024","journal-title":"Liver Int"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T10:21:32Z","timestamp":1733826092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524003081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":182,"alternative-id":["S0026049524003081"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156080","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156080"}}